KFAS
IRMD icon

Keating Financial Advisory Services’s iRadimed IRMD Stock Holding History

Keating Financial Advisory Services’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$382 Buy
4
+1
+33% +$91 ﹤0.01% 2376
2026
Q1 		$289 Buy
3
+2
+200% +$200 ﹤0.01% 2337
2025
Q4 		$97 Buy
+1
New +$86 ﹤0.01% 2129

Other funds holding IRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Keating Financial Advisory Services's IRMD Position: Q2 2026 in Review

Keating Financial Advisory Services increased its iRadimed (IRMD) stake by 33% in Q2 2026, buying an estimated $91 and bringing the position to 4 shares worth $382. The position accounts for ﹤0.01% of the portfolio, ranked #2376.

Keating Financial Advisory Services first reported a position in IRMD in Q4 2025 and has held it in 3 quarters since. 213 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

  • Keating Financial Advisory Services held 4 shares of iRadimed worth $382 as of Q2 2026.
  • Keating Financial Advisory Services bought 1 iRadimed share in Q2 2026, an estimated $91.
  • iRadimed made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2376 holding.
  • Keating Financial Advisory Services first reported a position in iRadimed in Q4 2025 and has held it in 3 quarters since.
  • 213 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.